Literature DB >> 34604978

Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.

M Wahid1, A Jawed, R K Mandal, H G Dailah, E M Janahi, K Dhama, P Somvanshi, S Haque.   

Abstract

OBJECTIVE: The current study reviewed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) variants for their effects on infection, transmission and neutralization by vaccine-induced antibodies.
MATERIALS AND METHODS: The research articles for the current study were searched over PubMed, Google Scholar, EMBASE and Web of Science online databases. The keywords used were: (("SARS-CoV-2" OR "COVID-19") AND ("mutation" OR "variant") AND ("death" OR "hospitalization" OR "infection" OR "transmission") AND ("antibody" OR "neutralize" OR "vaccine")). A total of 333 research articles were retrieved through online-database search. These articles were further scrutinized for their relevancy. Additionally, searches were performed to find the latest relevant information over Google search engine and relevant news browsers. Finally, around 35 germane articles were considered for scripting the current report.
RESULTS: The mutations have changed amino acids at key positions in spike protein viz. S477N, E484K, Q677H, E484Q, L452R, K417T, K417N and N501Y. These mutations are relevant for different characteristics and are present in newly evolved strains of SARS-CoV-2 like E484K in B.1.526, B.1.525, P.2, B.1.1.7, P.1 and B.1.351. Mutations have increased the immune escape potential leading to 3.5-6.5-folds decrease in neutralization of antibodies (Pfizer and Moderna vaccines). The variant, B.1.617 circulating in India and many other countries (double variant) having E484Q and L452R mutations, has raised the infection rate and decreased the neutralization capacity of the vaccine-induced antibodies. Deadly K417N+E484K+N501Y triplet mutations found in B.1.351 and P.1 have increased the transmission ability of these strains by 50% leading to greater COVID-19 hospitalization, ICU admissions and deaths.
CONCLUSIONS: The new SARS-CoV-2 variants have compromised the neutralization potential of the currently used vaccines, but still, they have considerable efficacy to reduce infection and mortality. GRAPHICAL ABSTRACT: https://www.europeanreview.org/wp/wp-content/uploads/Graphical_Abstract.jpg.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34604978     DOI: 10.26355/eurrev_202109_26805

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Multivalent Vaccine Strategies in Battling the Emergence of COVID-19 Variants.

Authors:  Paul C Guest
Journal:  Methods Mol Biol       Date:  2022

2.  Mortality Due to COVID-19 in Renal Transplant Recipients, Related to Variants of SARS-CoV-2 and Vaccination in Mexico.

Authors:  Juan Carlos H Hernández Rivera; Mariana Salazar Mendoza; Luis García Covarrubias; Ana Laura Quiroz Ramírez; Lizbeth Chicas Reyes; Manuel Bautista Hernández; Jorge Romero Martínez; Yohaheri Pineda Contla; Julissa Madai Velasco Durán; Agustín Trejo Rivas; Samantha Lorelae Rodríguez Flores; Walter Adolfo Querevalú Murillo; José Ramón Paniagua Sierra
Journal:  Transplant Proc       Date:  2022-06-01       Impact factor: 1.014

Review 3.  Emerging Trends in the Epidemiology of COVID-19: The Croatian 'One Health' Perspective.

Authors:  Tatjana Vilibic-Cavlek; Vladimir Stevanovic; Diana Brlek-Gorski; Ivana Ferencak; Thomas Ferenc; Magdalena Ujevic-Bosnjak; Irena Tabain; Natasa Janev-Holcer; Ivana Perkovic; Mario Anticevic; Barbara Bekavac; Bernard Kaic; Anna Mrzljak; Marin Ganjto; Ljiljana Zmak; Maja Mauric Maljkovic; Pavle Jelicic; Lovro Bucic; Ljubo Barbic
Journal:  Viruses       Date:  2021-11-24       Impact factor: 5.048

Review 4.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

Review 5.  Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.

Authors:  Manish Dhawan; Abhilasha Sharma; Nanamika Thakur; Tridib Kumar Rajkhowa; Om Prakash Choudhary
Journal:  Hum Vaccin Immunother       Date:  2022-05-04       Impact factor: 4.526

6.  Designing multi-epitope based peptide vaccine targeting spike protein SARS-CoV-2 B1.1.529 (Omicron) variant using computational approaches.

Authors:  Meet Parmar; Ritik Thumar; Jigar Sheth; Dhaval Patel
Journal:  Struct Chem       Date:  2022-09-20       Impact factor: 1.795

Review 7.  COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.

Authors:  Domenico Iacopetta; Jessica Ceramella; Alessia Catalano; Carmela Saturnino; Michele Pellegrino; Annaluisa Mariconda; Pasquale Longo; Maria Stefania Sinicropi; Stefano Aquaro
Journal:  Viruses       Date:  2022-03-10       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.